1 day Ago By Defense World Staff
Shares of LivaNova PLC ( NASDAQ:LIVN – Get Free Report ) have been assigned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company.
The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $70.80. LIVN has been the topic of a number of recent research reports.
Needham & Company LLC lifted their target price on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st.
Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $55.
00 to $66.00 in a report on Tuesday. Finally, Stifel Nicolaus boosted their target price on shares of LivaNova from $70.
00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Get Our Latest Stock Report on LivaNova Institutional Inflows and Outflows LivaNova Price Performance LivaNova stock opened at $51.
07 on Thursday. The company has a current ratio of 3.45, a quick ratio of 2.
94 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $2.
77 billion, a P/E ratio of -85.12 and a beta of 1.00.
The business has a 50-day moving average of $48.88 and a 200-day moving average of $53.42.
LivaNova has a 1 year low of $42.75 and a 1 year high of $64.47.
LivaNova ( NASDAQ:LIVN – Get Free Report ) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.
66 by $0.15. LivaNova had a positive return on equity of 13.
77% and a negative net margin of 1.37%. The company had revenue of $318.
60 million for the quarter, compared to analyst estimates of $305.05 million. On average, equities analysts anticipate that LivaNova will post 2.
58 EPS for the current year. About LivaNova ( Get Free Report LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.
The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. Further Reading Five stocks we like better than LivaNova How to Invest in Biotech Stocks How Much Can You Make in Stocks in One Month? Why Are Stock Sectors Important to Successful Investing? This Is the Top Large-Cap Stock Insiders Are Buying Top Biotech Stocks: Exploring Innovation Opportunities Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter .
.
